Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

273.08 -1.31 (-0.48%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
56 57 Next >
Amgen Inc. (NASDAQ: AMGN) Records 52-Week High Tuesday Morning
Via Investor Brand Network
3 Top ETFs I'm Planning to Buy Hand Over Fist in 2024, Despite All the Cheap Stocks on My Radar
I'm adding some ETFs to my retirement portfolio in 2024; here are the three I'm starting with. 
Via The Motley Fool
Topics ETFs Retirement
Amgen Stock Sees Relative Strength Rating Improve To 74
Amgen stock saw a positive improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 69 to 74. 
Via Investor's Business Daily
There Are Only 5 Dow Stocks I Wouldn't Buy in 2024
There's a lot to like about Apple, Microsoft, and most of the Dow Jones Industrial Average components in 2024. 
Via The Motley Fool
Topics Stocks
Amgen's Options: A Look at What the Big Money is Thinking
 
Via Benzinga
Analyzing Amgen In Comparison To Competitors In Biotechnology Industry
 
Via Benzinga
Is NASDAQ:AMGN a Good Fit for Dividend Investing?
Why AMGEN INC (NASDAQ:AMGN) is a Top Pick for Dividend Investors. 
Via Chartmill
Spotlight on Amgen: Analyzing the Surge in Options Activity
 
Via Benzinga
Looking Into Amgen's Recent Short Interest
 
Via Benzinga
Full Approval For Amgen's Flagship Cancer Drug Lumakras Pushed For Around Four Years
Amgen Inc (NASDAQ: AMGN) announced that the FDA has reviewed the company's supplemental New Drug Application, seeking full approval of the KRAS-blocking drug  
Via Benzinga
3 Biotech Stocks to Buy in the TradeSmith ‘Green Zone’
It's now time to take a look at these three biotech stocks to buy, as each one is currently within TradeSmith's "Green Zone." 
Via InvestorPlace
CRSP Stock Alert: CRISPR Therapeutics Is Losing Its Medical Chief
The fate of Crispr and CRSP stock will be determined by the success of other drugs in the company's pipeline rather than Casgevy. 
Via InvestorPlace
Amgen Provides Exposure To Obesity Drug At A Reasonable Price, Says Bullish Analyst
Amgen, Inc. (NASDAQ: AMGN) shares have been in focus amid developments in the AI-powered healthcare space. 
Via Benzinga
In-Depth Examination Of 18 Analyst Recommendations For Amgen
 
Via Benzinga
Uber To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Is Amgen Stock a Buy Now?
Boring businesses can be successful, too. 
Via The Motley Fool
Market Whales and Their Recent Bets on AMGN Options
 
Via Benzinga
Healthcare Sector Stocks: Consistent Above-Average Growth And Income
The healthcare sector is full of many really good companies with consistent, long term, above-average growth rates and many that have good, consistent, long-term dividend records. 
Via Talk Markets
1 Biotech Stock That Could Be the Next Amgen
The emergence of genomic medicine as a viable modality could transform this midcap biotech into the next Amgen. 
Via The Motley Fool
Better Growth Stock: Viking Therapeutics or Iovance Biotherapeutics?
Both of these pharma stocks could be big winners. But one stock screens as a better buy from a risk standpoint. 
Via The Motley Fool
PVH To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Insights Into Amgen's Performance Versus Peers In Biotechnology Sector
 
Via Benzinga
P/E Ratio Insights for Amgen
 
Via Benzinga
Looking Into Amgen's Recent Short Interest
 
Via Benzinga
Analyst Ratings for Amgen
 
Via Benzinga
1 Spectacular Dividend Stock Every Investor Should Consider
This biotech pioneer has been an exceptional growth and income stock. 
Via The Motley Fool
Why NASDAQ:AMGN is a Top Pick for Dividend Investors.
Why AMGEN INC (NASDAQ:AMGN) qualifies as a good dividend investing stock. 
Via Chartmill
Investigating Amgen's Standing In Biotechnology Industry Compared To Competitors
 
Via Benzinga
P/E Ratio Insights for Amgen
 
Via Benzinga
Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning
Biotech companies are edging closer to finding the answers behind Alzheimer's disease. 
Via Investor's Business Daily
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
56 57 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.